Carnegie acted as sole book-runner in the directed new share issue of 3.9 million new shares at a subscription price of NOK 20 per share. Biotec Pharmacon develops, manufactures and markets immune modulating compounds for the human health sectors and marine enzymes used in molecular biology.April 2014.
Healthcare
Directed new share issue in Biotec Pharmacon ASA (NO) — NOK 78 million
April 2014